Annexon adds Month 24 dual primary endpoint to Phase 3 ARCHER II trial of vonaprument in geographic atrophy
ANNX•ARCHER II trial expands success criteria
Annexon expanded its Phase 3 ARCHER II trial of vonaprument in geographic atrophy by adding a Month 24 dual primary endpoint.
Results have not been presented; a Data Monitoring Committee assessment of the Month 15 primary endpoint is expected in Q4 2026.
The change broadens the trial’s path to success by allowing efficacy at either Month 15 or Month 24.
Open-label extension to begin after Month 24
An open-label extension study will start, offering monthly vonaprument to patients completing Month 24 to assess longer-term safety and benefit.
Month 24 analyses are expected to complete in Q3 2027, setting up a later readout beyond the initial milestone.
